Welcome to our dedicated page for Im Cannabis news (Ticker: IMCC), a resource for investors and traders seeking the latest updates and insights on Im Cannabis stock.
IM Cannabis Corp. (Nasdaq: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany. The IM Cannabis news feed on Stock Titan aggregates company-issued press releases and other coverage related to its operations, strategy, governance, and capital markets activity.
Readers can expect frequent corporate updates, such as board and management changes, including appointments and departures of directors and executive officers. These announcements often detail the backgrounds of new appointees and outline how governance changes fit within the company’s broader strategic review.
The news stream also features financial reporting items, including notices about upcoming earnings releases and press releases summarizing interim financial results. These communications may discuss revenue trends, gross margin, non-IFRS measures such as Adjusted EBITDA, and commentary on factors affecting performance in Israel and Germany.
Another key category of coverage involves strategic and transactional developments. IM Cannabis has reported on initiatives to identify additional business opportunities, the signing of a non-binding term sheet to acquire a majority stake in a quantum computing bio data company, and its evaluation of potential expansion into the United States cannabis market, as well as possible divestitures of its German and Israeli operations. Capital markets updates, such as warrant amendments, resale registration statements, and Nasdaq listing compliance notices, are also part of the company’s news flow.
For investors and observers tracking IMCC, this page offers a centralized view of how the company communicates its progress in medical cannabis markets, its strategic review, and its responses to regulatory and market conditions. Users who follow IM Cannabis can use this news feed to monitor developments over time and review the company’s own descriptions of its plans and performance.
IM Cannabis Corp (NASDAQ: IMCC) reported preliminary financial results for Q4 and fiscal year 2021, with Q4 revenues exceeding $20 million, up over 37% from Q3 2021 and 308% year-over-year. For FY 2021, revenues reached at least $54 million, representing a 240% increase from FY 2020. The Q4 gross margin was approximately 18%, influenced by investments in Germany and COVID-19 impacts in Canada. The company plans to launch the WAGNERS brand in Germany and has signed an agreement to acquire Oranim, enhancing its position in the Israeli market.
IM Cannabis Corp. (NASDAQ: IMCC) has engaged MZ Group to enhance its investor relations and financial communications strategy. This collaboration aims to boost the company’s visibility and support its expansion in the global cannabis industry. MZ Group will assist in executing a comprehensive capital markets strategy, coordinating investor roadshows, and enhancing brand awareness. The agreement, initiated on February 1, 2022, includes a monthly fee of $14,000 and potential share issuance if it remains effective past August 1, 2022. IM Cannabis is operational across Israel, Canada, and Germany.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announces that Focus Medical has imported approximately 399 kg of premium Canadian cannabis from its subsidiary, TJAC. The product will be launched in the Israeli medical market by Q1 2022 under the WAGNERS brand, which holds a 5.6% market share in Ontario. CEO Oren Shuster highlights the achievement as a key milestone in the company's strategy, emphasizing the robust global supply chain and increasing demand for premium cannabis. This import is anticipated to be part of a consistent supply going forward.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) has announced managerial changes, including the appointment of Rinat Efrima as CEO of IMC Holdings, the company's Israeli subsidiary. Efrima, previously with Caesarstone and Kimberly-Clark, will focus on integrating recent acquisitions and driving growth. Yael Harrosh has been promoted to Chief Legal and Operations Officer, overseeing compliance and operations in the cannabis sector. These changes aim to strengthen leadership and enhance operational execution amid expansion in the Israeli market.
IM Cannabis plans to debut its WAGNERS brand in Germany's medical cannabis market in 2022, subject to regulatory approval. With expectations of strong demand for premium indoor-grown cannabis, the company is expanding its presence in one of the largest medical cannabis markets globally. The completion of a state-of-the-art logistics center through its subsidiary, Adjupharm GmbH, enhances its distribution capacity and operational capabilities in Germany, setting the stage for future growth.
IM Cannabis has announced the acquisition of a 51.3% stake in Oranim Plus Pharm Ltd., positioning the company as one of the largest medical cannabis retailers in Israel, with combined annualized revenues exceeding $44 million. Oranim, located in Jerusalem, generated approximately $16.5 million in revenue over the past year. The acquisition, valued at approximately NIS 11.94 million ($4.9 million), aims to enhance distribution capabilities and capitalize on market growth. The deal is expected to close by Q2 2022, pending necessary regulatory approvals.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announced that its recreational cannabis brand WAGNERS will be introduced in Israel following approval from the Israeli Ministry of Health for Focus Medical Herbs Ltd. to import premium cannabis from Trichome JWC Acquisition Corp. This move allows the import of an estimated 1,200 kilograms of cannabis throughout 2022. WAGNERS has shown significant market share growth in Canada, reaching 3.8% in Ontario. CEO Oren Shuster emphasized the strategic importance of this launch in enhancing the company's global supply chain and shareholder value.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announced the fourth installment of shares for the Panaxia Transaction, acquiring a license and pharmacy from Panaxia Pharmaceutical Industries for $7.2 million. The company issued 298,529 shares worth approximately $922,156 on November 16, 2021, at $3.089 per share. The acquisition, primarily paid with cash and shares, is part of IM Cannabis's strategy to strengthen its operational footprint in Israel, Germany, and Canada. The final share installment awaits approval from the Israeli Ministry of Health.
IM Cannabis Corp. (CSE:IMCC, NASDAQ:IMCC) reported Q3 2021 revenues of $14.4 million, a 30% increase from Q2 2021, while gross margins improved to 20% from 5.4%. Sales from WAGNERS and Highland Grow in Ontario surged over 110% from June to October. The company anticipates ongoing revenue growth into Q4 and 2022, driven by recent acquisitions and a strong market position. However, adjusted EBITDA loss was $7 million due to acquisition costs, and the net loss stood at $5.7 million, reflecting ongoing operational challenges.
IM Cannabis Corp (CSE:IMCC, NASDAQ:IMCC) announced the third installment of shares related to its acquisition of Panaxia-to-the-Home online pharmacy and trading center from Panaxia Pharmaceutical Industries. The overall purchase price stands at $7.2 million, combining $2.9 million in cash and $4.3 million in shares. The recent issuance of 248,212 shares at $3.225 each brings the total share value of this installment to approximately $905,306. This strategic acquisition enhances IM Cannabis's position in the growing cannabis market across Israel, Germany, and Canada.